{"id":46050,"date":"2025-10-23T11:20:12","date_gmt":"2025-10-23T09:20:12","guid":{"rendered":"https:\/\/www.satt.fr\/?p=46050"},"modified":"2025-10-23T11:21:16","modified_gmt":"2025-10-23T09:21:16","slug":"vitadx","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/vitadx\/","title":{"rendered":"La Success Story du mois : VITADX"},"content":{"rendered":"<div id=\"pl-46050\"  class=\"panel-layout\" ><div id=\"pg-46050-0\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-46050-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-0-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><span style=\"font-size: 14pt; color: #c90f4c;\">#<em>VitaDX, l\u2019intelligence artificielle au service du diagnostic du cancer de la vessie !<\/em><\/span><\/p><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-46050-1\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-46050-1-0\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-1-0-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"1\" ><img loading=\"lazy\" decoding=\"async\" width=\"163\" height=\"167\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/vitadx-xpath.jpg\" class=\"image wp-image-46053  attachment-full size-full\" alt=\"\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/vitadx-xpath.jpg 163w, https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/vitadx-xpath-146x150.jpg 146w, https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/vitadx-xpath-98x100.jpg 98w\" sizes=\"auto, (max-width: 163px) 100vw, 163px\" \/><\/div><\/div><div id=\"pgc-46050-1-1\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-1-1-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"2\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><strong>VitaDX, est une deeptech fran\u00e7aise pionni\u00e8re dans l'utilisation de l'IA et du traitement d'image appliqu\u00e9s \u00e0 la cytologie.<\/strong><\/p>\n<p>Cr\u00e9\u00e9e en 2015 afin de valoriser une technologie brevet\u00e9e, combinant l\u2019imagerie et l\u2019intelligence artificielle, la vocation et l\u2019ambition de VitaDX\u00a0est de d\u00e9velopper des solutions innovantes et performantes de diagnostic du cancer et ayant un impact significatif aux niveaux cliniques et m\u00e9dico \u00e9conomiques au b\u00e9n\u00e9fice du plus grand nombre de patients.<\/p>\n<div class=\"field__item\"><\/div>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-46050-2\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-46050-2-0\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-2-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"3\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h2 style=\"text-align: center;\" data-mce-style=\"text-align: center;\">D\u00e9tecter les cancers de la vessie gr\u00e2ce \u00e0 l'IA<\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-46050-3\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-46050-3-0\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-3-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"4\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p>Le cancer de la vessie repr\u00e9sente un d\u00e9fi m\u00e9dical majeur : il est souvent d\u00e9tect\u00e9 tardivement, ce qui complique la prise en charge et r\u00e9duit les chances de traitement efficace. Les examens actuels, comme l\u2019endoscopie, sont invasifs, inconfortables pour les patients et parfois co\u00fbteux pour les syst\u00e8mes de sant\u00e9. De plus, ces m\u00e9thodes traditionnelles peuvent manquer de sensibilit\u00e9 dans les stades pr\u00e9coces de la maladie, retardant ainsi la d\u00e9tection et la personnalisation du traitement.<\/p>\n<p>C\u2019est pour relever ce d\u00e9fi que la start-up <strong>VitaDX<\/strong>, accompagn\u00e9e et financ\u00e9e en maturation par la <strong>SATT Paris-Saclay<\/strong>, a mis au point\u00a0<strong>VisioCyt\u00ae Bladder<\/strong>, <strong>une innovation de rupture combinant analyse d\u2019images et intelligence artificielle<\/strong>. Ce test, marqu\u00e9 CE IVDR permet \u00e0 partir d\u2019un simple \u00e9chantillon d\u2019urine de d\u00e9tecter tr\u00e8s t\u00f4t les anomalies des cellules caract\u00e9ristiques d\u2019un cancer de la vessie.<\/p>\n<p>Non invasif, fiable et reproductible, VisioCyt\u00ae Bladder offre aux urologues un outil pr\u00e9cieux, parfaitement int\u00e9gr\u00e9 \u00e0 la pratique clinique, pour am\u00e9liorer la pr\u00e9cision et la rapidit\u00e9 du diagnostic.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-46050-4\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-46050-4-0\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-4-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"5\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h2 style=\"text-align: center;\">L'actualit\u00e9 de VitaDx<\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-46050-5\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-46050-5-0\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-5-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"6\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p>Le d\u00e9but d\u2019ann\u00e9e 2025 a marqu\u00e9 une \u00e9tape importante pour VitaDX avec un <strong>retour favorable de la HAS (Haute Autorit\u00e9 de Sant\u00e9)<\/strong> concernent la prise en charge d\u00e9rogatoire de VisioCyt\u00ae Bladder, la nomination de Fabrice Beauch\u00eane en tant que directeur g\u00e9n\u00e9ral et la poursuite du d\u00e9ploiement logistique avec Biogroup dans les r\u00e9gions autres que l\u2019Ile-de-France. <\/p>\n<p>La fin d\u2019ann\u00e9e 2025 et l\u2019ann\u00e9e 2026 s\u2019annoncent d\u00e9cisives : la soci\u00e9t\u00e9 poursuit une <strong>lev\u00e9e de fonds de 1,6M\u20ac<\/strong>, m\u00e8ne des discussions strat\u00e9giques avec la DGOS (Direction G\u00e9n\u00e9rale de l\u2019Offre de Soins) concernant le tarif du remboursement de la solution, pr\u00e9pare un d\u00e9veloppement \u00e0 l\u2019international via un laboratoire CLIA (Clinical Laboratory Improvement Amendments) tout en explorant de nouvelles applications de sa technologie (thyro\u00efde, autres d\u00e9pistages).<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-46050-6\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-46050-6-0\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-6-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"7\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h2 style=\"text-align: center;\">Entretien avec Fabrice Beauch\u00eane, Directeur g\u00e9n\u00e9ral de VitaDX<\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-46050-7\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-46050-7-0\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-7-0-0\" class=\"so-panel widget widget_sow-testimonials panel-first-child panel-last-child\" data-index=\"8\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-testimonials so-widget-sow-testimonials-default-238d510a4e96-46050\"\n\t\t\t\n\t\t><div class=\"sow-testimonials\">\n\t\t\t\t\t<div class=\"sow-testimonial-wrapper sow-user-left sow-layout-side\">\n\t\t\t<div class=\"sow-testimonial\">\n\t\t\t\t\n\t\t\t\t<div class=\"sow-testimonial-user\">\n\t\t\t\t\t\t\t\t\t\t<div class=\"sow-image-wrapper sow-image-wrapper-shape-round\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"sow-round-image-frame\" style=\"background-image: url( https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/1718236533257.jpeg );\"><\/div>\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"sow-text\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"sow-testimonial-name\"><strong><\/strong><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t<div class=\"sow-testimonial-text\">\n\t\t\t\t\t\t<p><strong>Pouvez-vous nous expliquer en quoi votre technologie d\u2019intelligence artificielle appliqu\u00e9e \u00e0 l\u2019analyse cellulaire constitue une avanc\u00e9e majeure par rapport aux m\u00e9thodes classiques de diagnostic du cancer de la vessie ?<\/strong><\/p>\n<p><em>Aujourd\u2019hui, l\u2019examen de r\u00e9f\u00e9rence pour diagnostiquer un cancer de la vessie reste l\u2019endoscopie, un acte invasif et souvent per\u00e7u comme inconfortable pour le patient. Avec VisioCyt\u00ae Bladder, nous proposons une approche totalement diff\u00e9rente : gr\u00e2ce \u00e0 l\u2019intelligence artificielle, il est d\u00e9sormais possible d\u2019analyser un simple \u00e9chantillon d\u2019urine et de pr\u00e9dire les r\u00e9sultats de l\u2019endoscopie et de l\u2019histologie. Cela ouvre la voie \u00e0 un diagnostic pr\u00e9coce et fiable, tout en \u00e9vitant un geste invasif. Nos performances sont d\u00e9j\u00e0 tr\u00e8s prometteuses et continueront de s\u2019am\u00e9liorer au fur et \u00e0 mesure que notre IA accumulera davantage de donn\u00e9es.<\/em><\/p>\n<p><strong>Quelles sont, selon vous, les principales retomb\u00e9es m\u00e9dicales et soci\u00e9tales de VisioCyt\u00ae Bladder pour les patients et les professionnels de sant\u00e9, aujourd\u2019hui et demain&nbsp;?<\/strong><\/p>\n<p><em>D\u00e8s aujourd\u2019hui, VisioCyt\u00ae Bladder permet d\u2019am\u00e9liorer la prise en charge des patients en r\u00e9duisant le recours syst\u00e9matique \u00e0 l\u2019endoscopie. Demain, ce test pourra devenir une v\u00e9ritable alternative \u00e0 cet examen, offrant une solution beaucoup moins invasive, plus confortable et mieux accept\u00e9e par les patients, ce qui favorisera une meilleure observance du suivi m\u00e9dical. Pour le syst\u00e8me de sant\u00e9, cela repr\u00e9sente \u00e9galement une source potentielle d\u2019\u00e9conomies, en r\u00e9duisant le recours aux actes lourds et co\u00fbteux gr\u00e2ce \u00e0 une prise en charge pr\u00e9coce.<\/em><\/p>\n<p><strong>Comment l\u2019accompagnement de la SATT Paris-Saclay a contribu\u00e9 au d\u00e9veloppement de VitaDX, et quelles sont vos ambitions dans les prochaines \u00e9tapes de d\u00e9ploiement (commercialisation, international, nouveaux produits) ?<\/strong><\/p>\n<p><em>L\u2019accompagnement de la SATT Paris-Saclay a \u00e9t\u00e9 d\u00e9terminant pour transformer une innovation de recherche en une solution concr\u00e8te pour les patients. Aujourd\u2019hui, notre priorit\u00e9 est d\u2019assurer le remboursement du test, ce qui permettra de le proposer sans reste \u00e0 charge pour les patients. Nous travaillons \u00e9galement \u00e0 l\u2019ouverture de nouveaux laboratoires partenaires afin de poursuivre notre d\u00e9ploiement \u00e0 l\u2019\u00e9chelle nationale. \u00c0 moyen terme, nous visons l\u2019international, avec notamment un CLIA aux \u00c9tats-Unis. Nous d\u00e9veloppons aussi de nouveaux produits, comme un kit de pr\u00e9l\u00e8vement \u00e0 domicile pour renforcer l\u2019accessibilit\u00e9, et nous explorons d\u00e9j\u00e0 d\u2019autres applications de notre technologie, comme dans le diagnostic du cancer de la thyro\u00efde. Notre ambition est claire : rendre le diagnostic du cancer plus performant, fiable et accessible au plus grand nombre de patients.<\/em><\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-46050-8\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-46050-8-0\"  class=\"panel-grid-cell\" ><div id=\"panel-46050-8-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"9\" ><div class=\"panel-widget-style panel-widget-style-for-46050-8-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p style=\"text-align: center;\"><a href=\"https:\/\/vitadx.com\/node\/3\"><strong><span style=\"color: #ffffff; font-size: 16pt;\"><span style=\"font-size: 16pt;\">D\u00e9couvrir VITADX<\/span><\/span><\/strong><\/a><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>#VitaDX, l\u2019intelligence artificielle au service du diagnostic du cancer de la vessie ! VitaDX, est une deeptech fran\u00e7aise pionni\u00e8re dans l&#8217;utilisation de l&#8217;IA et du traitement d&#8217;image appliqu\u00e9s \u00e0 la cytologie. Cr\u00e9\u00e9e en 2015 afin de valoriser une technologie brevet\u00e9e, combinant l\u2019imagerie et l\u2019intelligence artificielle, la vocation et l\u2019ambition de VitaDX\u00a0est de d\u00e9velopper des solutions [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":46051,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[535,603],"tags":[],"class_list":["post-46050","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-reussites","category-startup"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La Success Story du mois : VITADX - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/vitadx\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/vitadx\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/vitadx\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"headline\":\"La Success Story du mois : VITADX\",\"datePublished\":\"2025-10-23T09:20:12+00:00\",\"dateModified\":\"2025-10-23T09:21:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/vitadx\/\"},\"wordCount\":478,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/vitadx\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/la-successstory-du-mois-3.jpg\",\"articleSection\":[\"R\u00e9ussites\",\"Startup\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/vitadx\/\",\"url\":\"https:\/\/www.satt.fr\/vitadx\/\",\"name\":\"La Success Story du mois : VITADX - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/vitadx\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/vitadx\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/la-successstory-du-mois-3.jpg\",\"datePublished\":\"2025-10-23T09:20:12+00:00\",\"dateModified\":\"2025-10-23T09:21:16+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/vitadx\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/vitadx\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/vitadx\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/la-successstory-du-mois-3.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/la-successstory-du-mois-3.jpg\",\"width\":1793,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/vitadx\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La Success Story du mois : VITADX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\",\"name\":\"admin\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La Success Story du mois : VITADX - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/vitadx\/","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/vitadx\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/vitadx\/"},"author":{"name":"admin","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"headline":"La Success Story du mois : VITADX","datePublished":"2025-10-23T09:20:12+00:00","dateModified":"2025-10-23T09:21:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/vitadx\/"},"wordCount":478,"image":{"@id":"https:\/\/www.satt.fr\/vitadx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/la-successstory-du-mois-3.jpg","articleSection":["R\u00e9ussites","Startup"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/vitadx\/","url":"https:\/\/www.satt.fr\/vitadx\/","name":"La Success Story du mois : VITADX - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/vitadx\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/vitadx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/la-successstory-du-mois-3.jpg","datePublished":"2025-10-23T09:20:12+00:00","dateModified":"2025-10-23T09:21:16+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/vitadx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/vitadx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/vitadx\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/la-successstory-du-mois-3.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2025\/10\/la-successstory-du-mois-3.jpg","width":1793,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/vitadx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"La Success Story du mois : VITADX"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec","name":"admin","url":"https:\/\/www.satt.fr\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/46050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=46050"}],"version-history":[{"count":12,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/46050\/revisions"}],"predecessor-version":[{"id":46068,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/46050\/revisions\/46068"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/46051"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=46050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=46050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=46050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}